Not To Be Sniffed At: Dupixent Success In Rhinosinusitis Could Open Up Large Additional Market

On the brink of an expanded US approval for asthma, Sanofi/Regeneron’s interleukin-4 receptor blocker Dupixent has produced positive topline Phase III data in a lucrative third indication, rhinosinusitis with nasal polyps.